Literature DB >> 27932438

Squamous cell carcinoma of the extrahepatic bile duct with metachronous para-aortic lymph node metastasis successfully treated with S-1 plus cisplatin.

Ryohei Nishiguchi1, Dal Ho Kim2, Masayuki Honda2, Tsuguo Sakamoto2.   

Abstract

The most common histological classification of bile duct cancer is adenocarcinoma and squamous cell carcinoma (SCC) is relatively rare. We report a case of a 78-year-old man with SCC of the extrahepatic bile duct associated with metachronous para-aortic lymph node metastasis. He had undergone subtotal stomach-preserving pancreatoduodenectomy. The pathological findings demonstrated moderately differentiated SCC of the distal extrahepatic bile duct (T1N1M0, stage IIB). 6 months after surgery, recurrence of the para-aortic lymph node was shown in abdominal CT. 5 courses of tegafur/gimeracil/oteracil (S-1) plus cisplatin therapy was performed and the para-aortic lymph node disappeared, confirmed as complete response by imaging findings. The patient is alive without recurrence, 10 months after recurrence and chemotherapy. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27932438      PMCID: PMC5174907          DOI: 10.1136/bcr-2016-218177

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  24 in total

1.  Primary squamous cell carcinoma of the bile duct diagnosed by transpapillary cholangioscopy: case report and review.

Authors:  David Gatof; Yang K Chen; Raj J Shah
Journal:  Gastrointest Endosc       Date:  2004-08       Impact factor: 9.427

2.  [Series: Clinical study from Japan and its reflections; randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer].

Authors:  Akihiko Gemma
Journal:  Nihon Naika Gakkai Zasshi       Date:  2013-05-10

3.  Rapid development of cirrhosis secondary to squamous cell carcinoma of the common bile duct.

Authors:  P O Gulsrud; M Feinberg; R L Koretz
Journal:  Dig Dis Sci       Date:  1979-02       Impact factor: 3.199

4.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

5.  Squamous cell carcinoma of the common bile duct.

Authors:  R E Burger; W R Meeker; P M Luckett
Journal:  South Med J       Date:  1978-02       Impact factor: 0.954

Review 6.  Squamous cell carcinoma arising within a choledochal cyst.

Authors:  Leslie Price; Richard Kozarek; Nicholas Agoff
Journal:  Dig Dis Sci       Date:  2008-02-15       Impact factor: 3.199

7.  Squamous cell carcinoma of the proximal bile duct--a case report.

Authors:  G V Aranha; C V Reyes; H B Greenlee; T Field; J Brosnan
Journal:  J Surg Oncol       Date:  1980       Impact factor: 3.454

8.  A cholangiocellular carcinoma nude mouse strain showing histologic alteration from adenocarcinoma to squamous cell carcinoma.

Authors:  A Iemura; H Yano; A Mizoguchi; M Kojiro
Journal:  Cancer       Date:  1992-07-15       Impact factor: 6.860

9.  Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.

Authors:  T Okusaka; K Nakachi; A Fukutomi; N Mizuno; S Ohkawa; A Funakoshi; M Nagino; S Kondo; S Nagaoka; J Funai; M Koshiji; Y Nambu; J Furuse; M Miyazaki; Y Nimura
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

10.  Squamous cell carcinoma of the hilar bile duct.

Authors:  Ippei Yamana; Shunji Kawamoto; Shuji Nagao; Takahisa Yoshida; Yuichi Yamashita
Journal:  Case Rep Gastroenterol       Date:  2011-08-22
View more
  1 in total

1.  Nivolumab-induced systemic lymphadenopathy occurring during treatment of malignant melanoma: a case report.

Authors:  Tomoyo Kubo; Akihisa Hino; Kentaro Fukushima; Yoshimitsu Shimomura; Masako Kurashige; Shinsuke Kusakabe; Yasuhiro Nagate; Jiro Fujita; Takafumi Yokota; Hisashi Kato; Hirohiko Shibayama; Atsushi Tanemura; Naoki Hosen
Journal:  Int J Hematol       Date:  2022-02-24       Impact factor: 2.319

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.